Announcement under regulation 30 of SEBI(Listing Obligation and Disclosure Requirements) Regulations 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kimia Biosciences' Board has approved the appointment of Mr. Kaku Vijaya Shekhar Reddy as an Additional Director (Executive Director), effective December 29, 2025, subject to shareholder approval. Mr. Reddy brings over 40 years of experience in the pharmaceutical Active Pharmaceutical Ingredients (API) manufacturing sector, with prior senior roles including Managing Director, COO, and VP-Operations at other pharma companies. He is not related to any existing director on the board and is not debarred from holding a directorship by SEBI or any other authority. The board meeting concluded at 8:00 PM on the same day.
The appointment brings a seasoned pharma industry veteran into the leadership team, which could strengthen operational and strategic capabilities. For shareholders, this is a positive governance signal but requires ratification at the next general meeting.